How Cannabinoids Fight Inflammation: A Review of Recent Research | Research

The takeaway

Multiple classes of cannabinoids, including THC, CBD, and synthetic analogs, showed anti-inflammatory activity through a mechanism involving resolution-promoting eicosanoids.

Read this if you want to understand how cannabinoids reduce inflammation and why that mechanism differs from standard anti-inflammatory drugs.

All cannabinoid classes showed anti-inflammatory activity through a mechanism distinct from COX-2 inhibitors

What the researchers found

This review examined five years of research on the anti-inflammatory properties of cannabinoids across several categories: plant-derived cannabinoids (THC, CBD), synthetic analogs (ajulemic acid, nabilone), endocannabinoids (anandamide and related compounds), and non-cannabinoid cannabis components.

All classes demonstrated anti-inflammatory activity. The authors proposed a specific mechanism: cannabinoids increase the production of eicosanoids that promote the resolution of inflammation, rather than suppressing the eicosanoids that initiate inflammation (which is how COX-2 inhibitors work).

This distinction is important because promoting resolution is fundamentally different from blocking initiation, potentially offering a different therapeutic approach.

Why it matters

The proposed mechanism, promoting inflammation resolution rather than blocking initiation, distinguishes cannabinoids from conventional anti-inflammatory drugs like COX-2 inhibitors and suggests they may work through a complementary pathway.

The numbers in context

The review covered roughly 5 years of published research across phytocannabinoids, synthetic cannabinoids, endocannabinoids, and non-cannabinoid cannabis components.

How the study worked

This was a narrative review covering research published between approximately 2004 and 2009 on all classes of cannabinoids and their anti-inflammatory effects.

What this study cannot tell us

As a narrative review, this paper did not systematically assess study quality or risk of bias. The proposed mechanism involving resolution-promoting eicosanoids, while supported by evidence, was not definitively established.

How to read the evidence

Comprehensive review covering multiple cannabinoid classes, but narrative rather than systematic, with a proposed mechanism that needed further validation.

When this study was published

Published in 2009. The anti-inflammatory properties of cannabinoids have continued to be studied extensively, with many of these findings supported by subsequent research.

The bigger picture

Inflammation underlies many chronic diseases. If cannabinoids promote the resolution phase of inflammation through a mechanism distinct from existing drugs, they could represent a genuinely different therapeutic approach rather than just another version of existing anti-inflammatory medications.

Questions still open

Can the resolution-promoting mechanism be confirmed in clinical trials? Do different cannabinoids vary in their effectiveness for different types of inflammation? Could cannabinoids complement existing anti-inflammatory drugs?

Common questions

How do cannabinoids reduce inflammation differently from drugs like ibuprofen?

COX-2 inhibitors (like ibuprofen) block the production of molecules that start inflammation. Cannabinoids appear to increase the production of molecules that help resolve inflammation, a fundamentally different approach.

Which cannabinoid is best for inflammation?

The review found anti-inflammatory activity across all classes, including THC, CBD, synthetic analogs, and endocannabinoids, but did not directly compare their relative effectiveness.

Read the original research

Cannabinoids, endocannabinoids, and related analogs in inflammation.

The AAPS journal, 11(1), 109-19

View on PubMed ↗Publisher’s paper ↗

Citation

Burstein, Sumner H; Zurier, Robert B. (2009). Cannabinoids, endocannabinoids, and related analogs in inflammation.. The AAPS journal, 11(1), 109-19. https://doi.org/10.1208/s12248-009-9084-5